title: The prevalence of neurosensorial hearing loss among cystic fibrosis patients from Hospital de Clínicas de Porto Alegre.
abstract: Cystic fibrosis (CF) is considered one of the most prevalent lethal genetic disorders. The life expectancy of those patients has been rising. Besides the well-known prevalence of chronic rhinosinusitis, neurosensory hearing loss (NSHL) due to the large use of ototoxic antibiotics may be another problem that should receive special attention in otolaryngology (ENT).
  
  
  OBJECTIVE
  Define retrospectively the prevalence of NSHL among patients with CF from the Hospital de Clínicas de Porto Alegre (HCPA) and based on this data discuss the need for a specific out patient ENT-CF clinic.
  
  
  METHODS
  Files from CF HCPA patients were reviewed for age at diagnosis, the current age, types of antibiotics used, number of treatments, percentage with audiologic evaluation and its respective results.
  
  
  RESULTS
  One hundred and seven files were reviewed. The mean age at diagnosis was 1.33 years old (SD 1.97, range 0-12). The mean age of the sample was 7.87 (SD 4.49, range 1-22). Audiologic evaluation was performed in 39.3% (42) of the patients. 28.56% (12) had some degree of NSHL, while 36.3% did not present acoustic reflex. From 667 treatments with antibiotics, 49.5% were with tobramycin, 43.4% with amycacin and 7% with gentamicin.
  
  
  CONCLUSIONS
  The prevalence of NSHL among CF patients supports the need for a specific ENT-CF outpatient clinic. This clinic would help on the prevention and treatment of NSHL due to the use of ototoxic antibiotics and on the better understanding/control of rhinosinusal disorders.
authors.affiliation: ENT Hospital de Clinicas de Porto Alegre, Porto Alegre 90430-061, Spain. piltcher@yahoo.com
authors.forename: Otavio Bejzman
authors.initials: OB
authors.lastname: Piltcher
authors.forename: Vanessa Niemiec
authors.initials: VN
authors.lastname: Teixeira
authors.forename: Marcelo Wierzynski
authors.initials: MW
authors.lastname: de Oliveira
authors.forename: Isabella
authors.initials: I
authors.lastname: Scattolin
authors.forename: Simão Levin
authors.initials: SL
authors.lastname: Piltcher
mesh_terms: D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D003550:Cystic Fibrosis / Q000150:complications*; D005260:Female; D006319:Hearing Loss, Sensorineural / Q000453:epidemiology* / Q000209:etiology*; D006801:Humans; D007223:Infant; D008297:Male; D008499:Medical Records; D015995:Prevalence; D012189:Retrospective Studies; D013030:Spain / Q000453:epidemiology
chemical_list: D000900:Anti-Bacterial Agents